Endovascular Versus Medical Management of Atherosclerotic Renovascular Disease: Update and Emerging Concepts

Area of Science:

• Nephrology
• Cardiology
• Vascular Medicine

Background:

• Atherosclerotic renovascular disease is a leading cause of renovascular hypertension, particularly in aging populations and those with comorbidities like chronic kidney disease, heart failure, and coronary artery disease.
• It contributes to severe clinical issues, including flash pulmonary edema, progressive chronic kidney disease, and acute kidney injury.
• Management typically involves a combination of antihypertensive, antiplatelet, lipid-lowering, and optimized antidiabetic therapies.

Purpose of the Study:

• To review the limitations of previous studies on percutaneous renal angioplasty for atherosclerotic renovascular disease.
• To guide clinicians in identifying patients most likely to benefit from revascularization procedures.

Main Methods:

• Systematic review of randomized clinical trials, observational studies, and retrospective cohorts.
• Analysis of factors contributing to the discrepancy between initial enthusiasm and subsequent trial outcomes for renal artery angioplasty.
• Evaluation of diagnostic techniques, patient selection criteria, and procedural timing in revascularization studies.

Main Results:

• Randomized trials have largely failed to demonstrate significant benefits of percutaneous renal angioplasty over medical management for blood pressure, kidney function, and cardiovascular/renal outcomes.
• Previous positive findings from observational studies may be attributed to methodological limitations, including diagnostic heterogeneity and patient selection bias.
• Exclusion of patients with a higher likelihood of positive response may have contributed to the negative results in recent trials.

Conclusions:

• Percutaneous renal angioplasty for atherosclerotic renovascular disease has not consistently met expectations set by earlier research.
• Critical appraisal of study methodologies and careful patient selection are essential for future research and clinical decision-making regarding revascularization.
• Identifying specific patient subgroups who may still benefit from renal artery angioplasty remains a key clinical challenge.